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Abstract The methylotrophic yeast Pichia pastoris is
widely used for the production of recombinant glycopro-
teins. With the aim to generate biologically active
15N-
labeled glycohormones for conformational studies focused
on the unravelling of the NMR structures in solution, the P.
pastoris strains GS115 and X-33 were explored for the
expression of human chorionic gonadotropin (phCG) and
human follicle-stimulating hormone (phFSH). In agreement
with recent investigations on the N-glycosylation of phCG,
produced in P. pastoris GS115, using ammonia/glycerol-
methanol as nitrogen/carbon sources, the N-glycosylation
pattern of phCG, synthesized using NH4Cl/glucose–glycerol–
methanol, comprised neutral and charged, phosphorylated
high-mannose-type N-glycans (Man8–15GlcNAc2). However,
the changed culturing protocol led to much higher amounts
of glycoprotein material, which is of importance for an
economical realistic approach of the aimed NMR research.
In the context of these studies, attention was also paid to the
site specific N-glycosylation in phCG produced in P. pastoris
GS115. In contrast to the rather simple N-glycosylation
pattern of phCG expressed in the GS115 strain, phCG and
phFSH expressed in the X-33 strain revealed, besides neutral
high-mannose-type N-glycans, also high concentrations of
neutral hypermannose-type N-glycans (Manup-to-30GlcNAc2).
The latter finding made the X-33 strain not very suitable for
generating
15N-labeled material. Therefore,
15N-phCG was
expressed in the GS115 strain using the new optimized
protocol. The
15N-enrichment was evaluated by
15N-HSQC
NMR spectroscopy and GLC-EI/MS. Circular dichroism
studies indicated that
15N-phCG/GS115 had the same folding
as urinary hCG. Furthermore,
15N-phCG/GS115 was found
to be similar to the unlabeled protein in every respect as
judged by radioimmunoassay, radioreceptor assays, and in
vitro bioassays.
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2AB 2-Aminobenzamide
CD Circular dichroism
CHO Chinese hamster ovary
DMEM Dulbecco’s minimum essential medium
DO Dissolved oxygen
GLC-EI/MS Gas-liquid chromatography–electron impact
mass spectrometry
hCG Human chorionic gonadotropin
hFSH Human follicle stimulating hormone
HPLC High-performance liquid chromatography
HSQC Heteronuclear single quantum coherence
LH Luteinizing hormone
MAbs Monoclonal antibodies
MALDI-TOF-
MS
Matrix-assisted laser desorption ionization
time-of-flight mass spectrometry
NMR Nuclear magnetic resonance
PCR Polymerase chain reaction
phCG Human chorionic gonadotropin expressed in
Pichia pastoris
phFSH Human follicle stimulating hormone
expressed in Pichia pastoris
PNGase F Peptide-N
4-(N-acetyl-β-glucosaminyl)
asparagine amidase F
RIA Radioimmunoassay
RRA Radioreceptor assays
TIC Total ion current
TPPI Time proportional phase incrementation
wcw Weight cell weight
YPD Yeast peptone dextrose
Introduction
One of the popular host-cell systems for the expression of
recombinant proteins derived from eukaryotic genomes [1]i s
the methylotrophic yeast Pichia pastoris. This species,
which is able to perform post-translational modifications
such as glycosylation, is easier to manipulate genetically
and to culture than mammalian cells. The P. pastoris
expression system uses only pure reagents, such as
methanol, glucose or glycerol, biotin, trace salts, and water.
The media are free of toxins, and in addition bacterial
contaminations are prevented by the use of methanol, which
suits perfectly with pharmaceutical requirements. Further-
more, P. pastoris cell cultures can be grown at high cell
densities and protein purification is usually simple because
of the low level of native yeast proteins secreted [2].
Biologically active hCG and hFSH have successfully
been expressed in P. pastoris using the GS115 and X-33
strains, yielding phCG and phFSH, respectively [3, 4]
(unpublished data for the X-33 strain). The wild-type P.
pastoris X-33 strain has been created from the GS115 strain
by PCR of the wild type HIS4 gene, and transforming
GS115 to His+ by homologous recombination. The strains
X-33 and GS115 differ only by one basepair in the HIS4
gene. Recently, we have investigated in high detail the
glycosylation pattern of phCG expressed in P. pastoris
strain GS115, demonstrating the occurrence of (phosphor-
ylated) high-mannose-type structures [5].
The glycosylation studies on phCG, as mentioned above,
were carried out in the context of a larger project focused on
the unraveling of the NMR structures in solution of hCG and
hFSH. So far, this research has led to the unraveling of the
NMR structure in solution of the α-subunit of native, urinary
hCG [6–9], a structure that shows some differences with the
α-subunit in the crystal structure of hCG [10, 11]. Of
special interest is that the solution structure of the α-subunit
exhibits an increased structural disorder [8] compared to the
α-subunit in the crystal structure of the α,β-dimer.
In order to generate biologically active
15N-labeled
glycohormones in P. pastoris for NMR studies, in the
present paper an optimization of the earlier reported
fermentation protocol [4] is presented. Furthermore, attention
is paid to the influence of the GS115 and X-33 strains on the
N-glycosylation of P. pastoris-expressed hCG and hFSH.
Finally, the most optimal protocol and strain have been used
to generate biologically active
15N-labeled phCG.
Materials and methods
General
[
125I]NaI and [1,2,6,7,16,17-
3H]-testosterone were obtained
from Perkin Elmer Life Sciences (Boston, MA) and
15NH4Cl was purchased from Isotec (St Louis, MO). Pichia
expression vectors, yeast extract, peptone, and yeast
nitrogen base without amino acids, required for growing
P. pastoris cells, were obtained from Invitrogen Corp
(Carlsbad, CA).
All the DNA manipulations were according to standard
techniques [12]. For hCG expressions using the P. pastoris
strain GS115 and the pPIC9k expression vector, full details
have been reported [3, 4]. For expressions using the P.
pastoris strain X-33, the pGAPZalpha vector was used to
prepare phFSH/X-33 and phCG/X-33 (unpublished data).
Growth media
The preculturing of P. pastoris cells was carried out in YPD
(1% yeast extract, 2% peptone, and 2% dextrose), contain-
ing 100 μg/ml geneticin. The 1-liter medium for the cultur-
ing in the fermenter vessel contained 42.9 g KH2PO4,1g
CaSO4·2H2O, 14.3 g K2SO4, and 11.7 g MgSO4·7H2O. The
246 Glycoconj J (2008) 25:245–257nitrogen and carbon sources needed were prepared sepa-
rately. The medium used is an adaptation of the FM22
medium [13, 14], wherein (NH4)2SO4 has been substituted
by NH4Cl. To this end, 55 g NH4Cl were dissolved in
550 ml H2O, and the solution was sterilized by filtration
through a 0.22 μm filter. One hundred milliliter of this
solution were pumped into the fermenter vessel every 24 h
except on day 2, when 50 ml were pumped. A 200 ml
solution of 50% (w/v) glucose, containing 1 ml of PTM1
trace salts, replaced the previously used glycerol [4] during
the batch phase, and a 50% glycerol solution (2 g glycerol
in total) was used during the fed-batch phase of 20 min.
PTM1 consisted of 24 mM CuSO4,0 . 5 3m MN a I ,
19.87 mM MnSO4, 0.83 mM Na2MoO4, 0.32 mM boric
acid, 2.10 mM CoCl2, 0.15 mM ZnCl2, 0.23 mM FeSO4,
and 0.82 mM biotin.
Production of phCG in P. pastoris GS115
The production of phCG/GS115 was performed using a
BioFlo 3000 fermenter (New Brunswick Scientific, Edison,
NJ), equipped with a 3-liter bioreactor constantly maintained
at 28°C.
The P. pastoris cells were revived by inoculation from a
frozen glycerol stock of a single colony into 5 ml YPD,
containing 100 μg/ml geneticin (preculturing). After 2 days
of incubation at 30°C, 1 ml of the culture was transferred
into 100 ml of the same medium, and incubated for 3 days
at 30°C. Then, the culture was spun down at 5,000 rpm,
and the cells were resuspended in 10 ml of the supernatant.
After autoclaving the fermentation medium (1 l) in the
fermenter vessel, 100 ml of the NH4Cl solution, 50 ml of the
glucose solution (see above), and 6 ml of trace salts were
added in the vessel before inoculation of the cells. The pH
was automatically maintained at 5.0 by addition of 5.0 M
KOH. The agitation was set to 600 rpm, and O2 was
automatically mixed with air to maintain the dissolved
oxygen (DO) level at the set point of 30%. The console
automatically adjusted the gas flow, varying between one
and two vessel volume. The cell density was estimated every
24 h by measuring the wet cell weight and the absorbance at
600 nm. Foaming was prevented by the addition of 100 μl
Antifoam 289. The culture used the glucose present in the
vessel in about 3.5 h, and then the glucose feeding was
gradually adjusted according to the DO reading at 6 ml/h.
The cells started to utilize O2 while they were actively
growing, the agitation was set to 750 rpm, and towards the
end of the batch phase they were utilizing 90% of pure O2.
In total, 100 g of glucose was used during this batch growth
phase, which lasted for about 20 h. Then, when all the
glucose was consumed, an increase in both DO and pH was
observed. The glycerol fed-batch phase was initiated by
feeding the culture with the glycerol solution and lasted
20 min. The cells were starved for 30 min before starting the
induction phase. Then, the culture was fed with a 50% (v/v)
methanol solution (containing 6 ml/l of trace salts) at a rate
of 6 ml/h. Once the culture was adapted to grow on
methanol, the rate was increased and the feeding solution
was replaced by a 90% (v/v) methanol solution (containing
6 ml/l of trace salts). DO spikes were regularly monitored to
ensure the viability of the culture; the induction phase lasted
96 h.
At the end of the fermentation, the pH of the medium was
adjusted to 7.4, EDTA and NaN3 were added to a concentra-
t i o no f1 0a n d1m M ,r e s p e c t i v e l y ,a n dt h ec e l l sw e r e
separated from the 3-liter of supernatant by centrifugation at
5,000 rpm with a Beckman centrifuge for 20 min at 20°C.
phCG/GS115 was purified using an earlier described
protocol using sequential Phenyl Sepharose (Amersham
Biosciences, Piscataway, NJ) and SP-Sepharose Fast Flow
(Amersham Biosciences) column chromatography [4],
yielding about 25 mg/l full biological active glycohormone.
Production of phCG and phFSH in P. pastoris X-33
T h ep r o d u c t i o no fp h C G / X - 3 3a n dp h F S H / X - 3 3w a s
carried out in a 10-liter fermentor vessel using ammonia/
glycerol–methanol as nitrogen/carbon sources (unpublished
data of R.R. Dighe), yielding about 17 and 22 mg/l biological
active glycohormone, respectively.
Release and isolation of N-glycans of phCG and phFSH
with PNGase F or Endo H
Glycoprotein samples (phCG or phFSH) were reduced and
S-carboxymethylated according to standard procedures [5,
15], except that the reducing glycoprotein solution was
boiled for 3 min instead of being incubated for 2 h at 37°C.
Reduced and carboxymethylated glycoprotein orglycopep-
tide (derived from phCG) samples were dissolved (2 mg/ml)
in 20 mM NaH2PO4/Na2HPO4, pH 7.2, containing
10 mM EDTA, and digested with peptide-N
4-(N-acetyl-β-
glucosaminyl)asparagine amidase F (PNGase F, EC 3.5.1.52;
Roche Applied Science, IN) (0.5 U/mg) for 24 h at 37°C.
Alternatively, samples were dissolved (2 mg/ml) in 20 mM
NaH2PO4/Na2HPO4, pH 5.5, containing 10 mM EDTA, and
digested with endo-β-N-acetylglucosaminidase H (Endo H,
EC 3.2.1.96; Roche Applied Science, IN) (1 mU/100 μg).
For the N-glycan profiling of phCG/GS115, the PNGase
F digest was separated on a Superdex G75 column (60×
2.6 cm; Pharmacia, Uppsala, Sweden) using 50 mM
NH4HCO3, pH 7.0, as eluent at a flow rate of 1 ml/min,
monitored at 214 nm (Uvicord, LKB). In the case of phCG/
X-33 and phFSH/X-33, the PNGase F digest was fraction-
ated on a Bio-Gel P-10 column (75×2 cm, BioRad) using
50 mM NH4HCO3, pH 7.0, as eluent at a flow rate of
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8100 RI detector). The N-deglycosylated glycoproteins and
the carbohydrates were isolated and lyophilized four times.
N-glycans released from glycopeptides were directly
labeled with 2-aminobenzamide (2AB) without prior
separation from the peptide moiety.
Preparation, isolation, and fractionation of phCG/GS115
glycopeptides
Reduced and carboxymethylated phCG/GS115 (15 mg), dis-
solved in 7.5 ml 20 mM NaH2PO4/Na2HPO4,p H8 . 0 ,w a s
digested with 100 μg trypsin (EC 3.4.21.4; Roche Applied
Science, IN) for 2 h at 37°C. The digest was stored for 20 min
at −80°C to deactivate the enzyme, then lyophilized. The
tryptic digest was dissolved in buffer A (20 mM Tris/HCl,
pH 7.5, containing 0.3 M NaCl, 1 mM CaCl2,1m MM n C l 2,
and 0.02% NaN3) and applied to a 2-ml ConA-Sepharose
(Sigma-Aldrich, St Louis, MO) column, equilibrated in the
same buffer. After washing with buffer A, the column was
eluted with 100 mM methyl α-D-mannopyranoside in buffer
A, and the glycopeptide-containing fraction obtained was
lyophilized.
HPLC fractionations were carried out on a Waters 600
HPLC system. The glycopeptide fraction was separated on a
Vydac 214TP510 C4 column (4.6×250 mm; Grace Vydac,
Hesperia, CA). Elutions were performed with a gradient of
acetonitrile in 0.1 M triethylamine phosphate, pH 6.5 (built
up from buffers B and C), at a flow rate of 1.5 ml/min,
monitored at 214 nm. Buffer B consisted of 5% acetonitrile
in 0.1 M triethylamine phosphate, pH 6.5; buffer C of 60%
acetonitrile in 0.1 M triethylamine phosphate, pH 6.5. For
gradient details, see relevant figure captions. Isolated glyco-
peptides were desalted on a HiTrap column (Pharmacia), then
lyophilizedthreetimes.OneoftheVydacfractionswasfurther
fractionated on a Lichrosorb-NH2 10 μmc o l u m n( 2 5 ×
0.46 cm, Alltech, Breda, The Netherlands), equipped with
a LiChrospher Amino 5 μm guard column (7.5×4.6 mm).
Elutions were performed with a gradient of 30 mM K2HPO4/
KH2PO4, pH 6.8, in acetonitrile, at a flow rate of 1.5 ml/min,
monitored at 214 nm. Relevant fractions were concentrated
under a N2 stream, and lyophilized.
Characterization of
15N-phCG/GS115
SDS-PAGE
The purity of
15N-phCG/GS115 was checked by SDS-
PAGE under reducing conditions. The gel was composed of
a 4% stacking gel at pH 6.8 and a 12% running gel at
pH 8.8. The bands were visualized with Coomassie Blue.
Radioimmunoassay (RIA)
The hCG activity of the purified
15N-phCG/GS115 material
was determined by RIA using various polyclonal and
monoclonal antibody-based RIAs as described earlier
[3, 16]. Predetermined quantities of urinary hCG or purified
15N-phCG/GS115 material were diluted in RIA buffer
(0.5 M sodium phosphate buffer, pH 7.4, containing
150 mM NaCl and 50 mM EDTA), then incubated with
appropriate dilutions of either hCG polyclonal antiserum or
monoclonal antibodies against hCG and [
125I]hCG
(100,000 cpm/tube) overnight at room temperature. The
antigen-antibody complexes were precipitated by adding an
appropriate dilution of normal rabbit/ mouse serum, goat
anti-rabbit/ anti-mouse IgG and 2.5% polyethylene glycol.
The tubes were centrifugated at 5,000×g, the supernatant
was discarded, and the radioactivity in the pellet was
counted in a gamma counter.
Radioreceptor assays (RRA)
The ability of
15N-phCG/GS115 to bind to luteinizing
hormone (LH) receptors was assayed by RRA, using a
crude rat testicular homogenate as a source of LH receptors
[3, 17]. The receptor preparation was incubated with
varying concentrations of
15N-phCG/GS115 or urinary
hCG in the presence of [
125I]hCG (200,000 cpm/tube) as
the tracer. The non-specific binding was determined by
evaluating the binding of [
125I]hCG to the receptor in the
presence of a large excess of unlabeled hCG (400 ng/ml).
The samples were incubated at room temperature for 2–3h ,
followed by addition of 1 ml RRA buffer consisting of
0.05 M phosphate buffer, pH 7.4, containing 5 mM MgCl2
and 1 mg/ml BSA. The samples were centrifugated for
15 min at 4,000×g at 4°C. The supernatant was discarded
and the pellet was counted using a Perkin Elmer auto-
gamma counter.
Mouse Leydig cell in vitro bioassay
The ability of
15N-phCG/GS115 to stimulate testosterone
production in mouse Leydig cells, obtained from adult
male Swiss mice (2–3 months old) was assayed as
described [17]. Testes were decapsulated, suspended in
Dulbecco’s minimum essential medium (DMEM), pH 7.4,
containing 0.05 M Hepes and 0.1% bovine serum
albumin, and stirred in an ice bath on a magnetic stirrer
for 15 min. The cell suspension per testis was filtered
through a nylon cloth, oxygenated, and incubated for 1 h
at 34°C (shaking water bath). After centrifugation for
10 min at 750×g, the cells were washed twice with
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of the cell suspension (0.4 ml/tube) were incubated with
different dilutions of
15N-phCG/GS115 or urinary hCG for
4 h at 34°C (shaking water bath) following oxygenation.
Testosterone, secreted upon stimulation with
15N-phCG/
GS115 or urinary hCG, was determined by a testosterone
specific RIA, as described earlier [17], using specific
testosterone antiserum (at 1:50,000 dilution) and
[1,2,6,7,16,17-
3H]-testosterone (6,000 cpm/tube) in a total
volume of 400 μl. Binding reactions were carried out for
1ha tr o o mt e m p e r a t u r ef o l l o w e db y1ha t4 ° C .A tt h e
end of the incubation period, free testosterone was
removed by adding an equal volume of dextran-coated
charcoal (1 g charcoal and 0.1 g dextran/ml). Subsequent-
ly, the tubes were centrifugated at 5,000×g for 15 min at
4°C. 700 μl of each supernatant were thoroughly mixed
with 1 ml scintillation cocktail (2.5 g 2,5-diphenyloxazole,
200 mg p-bis[2-(5-phenyloxazolyl)]-benzene, 10.5 ml
methanol in 500 ml toluene). The solutions were incubat-
ed at room temperature in the dark for at least 4 h, and
radioactivity was counted in a Pharmacia Liquid Scintil-
lation counter.
Analysis methodologies
Monosaccharide analysis
Desaltedglycoproteinsamplesweresubjectedtomethanolysis,
f o l l o w e db yr e - N-acetylation and trimethylsilylation, and the
generated mixtures of trimethylsilylated methyl glycosides
were analyzed by GLC-EI/MS, as described [5, 18].
Methylation analysis
The hypermannose-type chain fraction derived from
phFSH/X-33 (1 mg) was permethylated using methyl
iodide and solid sodium hydroxide in dimethyl sulfoxide.
After hydrolysis, the mixture of partially methylated
monosaccharides was converted into a mixture of partially
methylated alditol acetates, which was analyzed by GLC-
EI/MS, as described [19, 20].
2AB-labeling of N-glycans and HPLC profiling
Enzymatically released glycoprotein N-glycans were deriv-
atized with 2-aminobenzamide, as described [5, 21].
Neutral N-glycan profiling on normal phase TSKgel
Amide-80 and charged N-glycan profiling on weak anion-
exchange Vydac 301 VHP5410 were carried out as reported
previously [5].
Matrix-assisted laser desorption ionization time-of-flight
mass spectrometry
MALDI-TOF mass spectra were recorded on a Voyager-DE
PRO mass spectrometer (Applied Biosystems, Nieuwerkerk
aan de IJssel, The Netherlands) with implemented delayed
extraction technique, equipped with a N2 laser (337 nm,
3 ns pulse width). Spectra (positive-ion mode) were
recorded in the linear mode at an accelerating voltage of
25 kV using an extraction delay of 600 ns. Peptide samples
(0.5 μl), when necessary desalted with Omix tips C18
(Varian, Lake Forest, CA), were mixed in a 1:1 ratio on the
target with α-cyano-4-hydroxycinnaminic acid (10 mg/ml)
dissolved in acetonitrile—0.3% aqueous trifluoroacetic acid
(50:50, v/v).
15N-phCG/GS115 (2 mg/ml) was dissolved in
0.2% trifluoroacetic acid and boiled for 3 min. Then, 0.5-μl
samples were mixed in a 1:1 ratio on the target with 3,5-
dimethoxy-4-hydroxycinnaminic acid (sinapinic acid,
10 mg/ml) dissolved in acetonitrile—0.3% aqueous tri-
fluoroacetic acid (50:50, v/v).
Amino acid analysis
15N-phCG/GS115 (400 μg) was hydrolyzed in 6 M HCl at
110°C for 22 h. After trimethylsilylation, the derivatized
amino acids were analyzed by GLC-EI/MS on a Fisons
Instruments GC 8060/MD 800 system (Interscience),
equipped with an AT-1 column (30 m×0.25 mm, Alltech,
Breda, The Netherlands). The temperature was maintained
for 2 min at 80°C, and then increased at 4°C/min until 180°C,
which was kept for 5 min.
Circular dichroism (CD)
Samples were prepared by dissolving 0.5 mg
15N-phCG/
GS115 in 300 μl 50 mM sodium phosphate buffer, pH 5.6.
CD measurements were carried out between 260 and
190 nm at room temperature on a Jasco J-810 spectropo-
larimeter, using a 1-mm path length cell, 1-nm bandwidth,
1-s response time, and a scan speed of 50 nm/min.
NMR spectroscopy
NMR spectra were recorded on a 900-MHz NMR spec-
trometer (Bruker Avance DRX). Lyophilized
15N-phCG/
GS115 (15 mg) was dissolved in 500 μl 90% (v/v) H2O,
containing 10 mM EDTA and 10%
2H2O (99.9%; Cam-
bridge Isotope Laboratories Inc., MA). The
15N-HSQC
spectrum was recorded at a probe temperature of 57°C and
pH 4.4, using Echo/Antiecho-TPPI gradient selection with
Glycoconj J (2008) 25:245–257 249decoupling during acquisition [22–24]. The experiments
were obtained with 128×1024 points, 128 scans using a
spectral width of 2737 Hz in the
15N dimension and
9920 Hz in the
1H direction. NMR data sets were processed
using in house developed software with zero filling, π/2
shifted sine bell window function for t1, π/2 shifted squared
sine bell window function for t2, and automatic spline
baseline correction in both dimensions.
Results and discussion
Optimization of the production of recombinant phCG
in P. pastoris GS115
In general, P. pastoris can provide high expression levels of
foreign proteins [3, 13], being strongly dependent on the
methanol-regulated promoter of the alcohol oxidase 1 gene
(AOX1) [25, 26]. In order to produce
15N-labeled glyco-
hormones in an economical way, an optimization of earlier
protocols [4, 14, 27] was investigated. Due to the high costs
of
15N-labeled ammonia, the use of ammonia was not
explored. Although both
15NH4Cl and (
15NH4)2SO4 are
equally priced, the use of (NH4)2SO4 results in a precipi-
tation of K2SO4, which can hamper cell growth. As an
exchange of medium would be required during the
fermentation to remove K2SO4 [27],
15NH4Cl was selected
instead. Looking for a reduction of the costs of a potential
13C labeling, introductory experiments showed that partial
replacement of glycerol [14, 28] by glucose turned out to be
an excellent option. Therefore, in the present work the
nitrogen/carbon sources NH4Cl/glucose-glycerol-methanol
were explored to replace the earlier used [4] ammonia/
glycerol-methanol. The finally developed production pro-
cess, yielding the highest cell densities and yields (about
25 mg/l phCG/GS115) so far, has been detailed in
“Materials and methods.”
For protein expression in P. pastoris, it is crucial to supply
an optimal amount of NH4Cl. However, continuous diluted
NH4Cl feeding was not explored. Previous protocols [14]
recommended to feed the culture every 24 h with 10 g/l of
NH4Cl. Following this strategy, however, we found that on the
second day of the fermentation, 5 g/l were enough to ensure
acidification of the medium by the cells because there was no
change in the DO. The short glycerol fed-batch phase of
30 min was long enough to derepress the AOX1 promoter
[14]. At the end of the batch phase (48 h), just before methanol
induction, the wet cell weight (wcw) reached 109 g/l (Fig. 1),
and 48 h after the beginning of the methanol induction, the
wcw reached 233 g/l, then decreased to 198 g/l because of the
dilution effect. It should be noted that this is the first time that
such high cell densities are reported for recombinant glyco-
protein hormones in P. pastoris. This is probably due to the
use of NH4Cl instead of ammonia [4]o r( N H 4)2SO4 for which
in both cases the highest wcw never exceeded 62 g/l (OD 150)
(unpublished data). During the adaptation phase of the
methanol induction, 50% aqueous methanol was supplied at
a flow rate of 6 ml/h for 8 h. The choice of diluted methanol
was to avoid a toxic methanol accumulation, which would
provoke cell death. Methanol feeding was progressively
increased in order to maintain a good O2 drop, and after
30 h, a solution of 90% aqueous methanol was used as carbon
source.
Summarising, a highly efficient protocol using the
nitrogen/carbon sources NH4Cl/glucose-glycerol-methanol
for the production of phCG in P. pastoris GS115 could be
established.
Comparison of the N-glycan profiles of phCG/GS115,
phCG/X-33, and phFSH/X-33
Recently, we have investigated the glycosylation pattern of
phCG/GS115 expressed in P. pastoris strain GS115 using
ammonia/glycerol-methanol as nitrogen/carbon sources [5].
The N-glycans consisted of neutral (80%) and charged,
phosphate-containing (20%) high-mannose-type structures.
Mannosyl O-glycans were not detected. Neutral oligo-
saccharides were composed of Man8GlcNAc2 (11%),
Man9GlcNAc2 (47%), Man10GlcNAc2 (28%), Man11GlcNAc2
(10%), Man12GlcNAc2 (4%), and traces of Man13–15
GlcNAc2. Mono- and di-phosphate-containing oligosaccha-
rides were present, whereby the mono-phosphate compounds
ranged from Man9PGlcNAc2 to Man13PGlcNAc2.F o rt h e
detailed isomer composition of the various Man8–11GlcNAc2
ensembles, see [5].
In order to search for differences in N-glycosylation
when glycoprotein hormones are expressed in P. pastoris
strain GS115 or X-33, of importance for future NMR
studies, N-glycan screenings were carried out on the phCG/
GS115 (new conditions), phCG/X-33, and phFSH/X-33
Time (h)
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24
Fig. 1 Growth curve of Pichia pastoris cells during the fermentation
with NH4Cl/glucose–glycerol–methanol as nitrogen/carbon sources
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GS115 revealed a carbohydrate content of 30% (by mass),
and the presence of Man and GlcNAc in the molar ratio of
9:2, comparable with phCG/GS115 when using ammonia/
glycerol-methanol as nitrogen/carbon sources [5]. However,
monosaccharide analysis of phCG/X-33 and phFSH/X-33
revealed a carbohydrate content of 37 and 39% (by mass),
respectively, and Man and GlcNAc were present in the
molar ratio of 33:2 and 36:2, respectively. In view of the
relatively high amounts of mannose found, the possible
presence of free mannose in the samples was excluded via
an additional purification by size-exclusion chromatogra-
phy (Hitrap). As no differences were found between the
first and the second monosaccharide analysis of each probe,
these data indicate the presence of hypermannosylation in
both phCG/X-33 and phFSH/X-33.
After reduction and carboxymethylation, the three
samples were digested with PNGase F, and the complete-
ness of the N-deglycosylation was checked by SDS-PAGE.
In the case of phCG/GS115, the pool of released N-
glycans was isolated via size-exclusion chromatography,
then 2AB-labeled, and analyzed by HPLC. The molar ratio
of Man8GlcNAc2:Man9GlcNAc2:Man10GlcNAc2:Man11
GlcNAc2 was shown to be 19:38:27:16. Glycans larger
than Man11GlcNAc2 were present in negligible amounts.
Evidently, the neutral N-glycosylation patterns of the
phCG/GS115 batches prepared using the nitrogen/carbon
sources NH4Cl/glucose–glycerol–methanol (this study) and
ammonia/glycerol–methanol [5] contain the same compo-
nents, although in slightly different molar ratios. The same
holds for the charged N-glycans. Note that the Man9
GlcNAc2 isomer mainly represents [5]:
Man(α1-2)Man(α1-6)
      \
      Man(α1-6)
      / \
            Man(α1-3) Man(β1-4)GlcNAc(β1-4)GlcNAc
/
Man(α1-2)Man(α1-2)Man(α1-3)
      /
Man(α1-6)
In the case of phCG/X-33 and phFSH/X-33, the pools of
N-glycans were fractionated by size-exclusion chromatog-
raphy, yielding three fractions, denoted P10.1, P10.2, and
P10.3 (Fig. 2). Fraction P10.1 contained the protein moiety.
Monosaccharide analysis demonstrated the occurrence of
carbohydrate in fractions P10.2 (Man:GlcNAc=33:2 for
phCG/X-33, and 36:2 for phFSH/X-33) and P10.3 (Man:
GlcNAc=10:2 for both samples); fraction P10.2 contained
small amounts of protein.
HPLC profiling of the 2AB-labeled P10.3 fractions
derived from phCG/X-33 and phFSH/X-33, showed in both
cases a series of neutral oligomannose-type N-glycans,
ranging from Man9GlcNAc2 to Man11GlcNAc2 (Fig. 3a
and b); molar ratios of Man9GlcNAc2:Man10GlcNAc2:
Man11GlcNAc2 are 43:39:17 for phCG/X-33, and 40:42:18
for phFSH/X-33. Comparing Fig. 3a and b, it is postulated
that phCG/X-33 and phFSH/X-33 present slight differences
in their Man10GlcNAc2 and Man11GlcNAc2 isomeric pop-
ulations. In contrast to phCG/GS115 [5], phCG/X-33 and
phFSH/X-33 did not contain phosphorylated N-glycans.
Fraction P10.2 of phFSH/X-33 was subjected to meth-
ylation analysis, and it was found that the P10.2 glycans are
built up from terminal Man, 2-substituted Man, and 2,6-
disubstituted Man in the molar ratio 1.2:2.3:1.0; very small
amounts of 6- and 3,6-di-substituted Man were detected. It
should be noted that, as expected, the hypermannose-type
4T i m e (h)
RI detection 
P10.2 
P10.1 
P10.3 
0 6
Fig. 2 Bio-Gel P-10 fractionation pattern of PNGase F-treated
phFSH/X-33. Elutions were performed at a flow rate of 13 ml/h and
monitored by refractive index detection. A similar profile was
obtained with phCG/X-33. Peak 1, protein; peak 2, hypermannose-
type N-glycans; peak 3, high-mannose-type N-glycans
a
b
55 60 65 70 75 80
Fluorescence  
Time (min) 
M9GN2 
M10GN2 
M11GN2 
Fig. 3 HPLC profile of 2AB-labeled neutral oligosaccharides derived
from glycoprotein samples expressed in strain X-33 on a normal-phase
TSKgel Amide-80 column. Elutions were carried out with a gradient of
ammonium formate, pH 4.4, in acetonitrile, at a flow rate of 0.8 ml/min
[5]. a N-glycans of phCG/X-33; b N-glycans of phFSH/X-33. M =
Man, GN = GlcNAc. Under the applied conditions, the acidic
compounds elute in the void volume, not shown in the chromatograms
Glycoconj J (2008) 25:245–257 251chains did not contain (α1–3)-linked Man residues in the
outer part [29].
Based on the finding of hypermannosylation when using
the X-33 strain, the GS115 strain, yielding a more simple
N-glycosylation pattern, was selected for generating
15N-
labeled phCG for NMR studies.
This is the first glycosylation study on glycoproteins
expressed in the P. pastoris wild type X-33 strain, a strain
that has become commercially available recently. The found
hypermannosylation confirms the recent findings of [30] for
the glycosylated chicken cystatin expressed in the X-33
strain, whereby hypermannose-type N-glycans up to 50
Man residues were indicated. Probably, the difference of
one basepair in the HIS4 gene of the X-33 strain causes a
frame shift, and therefore induces translation modifications.
P. pastoris strains are generally preferred to Saccharomyces
cerevisiae strains, because they were known for their
suitability to express recombinant glycoproteins with only
high-mannose-type, and not hypermannose-type N-glycans.
With the introduction of the P. pastoris wild type X-33
strain, one should really realize the differences in glycosyl-
ation machinery among P. pastoris strains.
Site-specific N-glycosylation of phCG/GS115
phCG/GS115 (N-glycosylation sites at αAsn52, αAsn78,
βAsn13, and βAsn30) was reduced, carboxymethylated,
and digested with trypsin. The resulting mixture of peptides
and glycopeptides was subjected to ConA-Sepharose
chromatography, and the glycopeptide-containing fraction,
eluted with 100 mM methyl α-D-mannopyranoside, was
subjected to HPLC analysis, yielding 3 subfractions
denoted 1, 2, and 3 (Fig. 4). Each subfraction was digested
with either PNGase F or Endo H, and analyzed by positive-
ion mode MALDI-TOF-MS. Under these conditions, being
specific for peptides, released carbohydrates are not
detected as they do not crystallize with the matrix and/or
fail to protonate. Due to the limited amount of material
available, attention was paid only to the neutral N-glycans,
representing 80% of the total N-glycan pool. Fraction 1,
digested with PNGase F, presented [M+H]
+ signals at m/z
1373.2 and 2070.9, corresponding to the peptides β9–20
and α76–92, respectively [31, 32]. Amino acid analysis
performed on fraction 1 revealed the presence of about 50%
β9–20 and 50% α76–92. Subfractionation of fraction 1 on
Lichrosorb-NH2 yielded 2 fractions, denoted 1-1 and 1-2.
MALDI-TOF-MS analysis of these fractions, digested with
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Fig. 4 HPLC elution profile at 214 nm of the phCG/GS115-derived
tryptic glycopeptide fraction on a reversed-phase Vydac C4 column.
Elutions were carried out with a gradient of 0–80% (v/v) solvent C
[60% acetonitrile in triethylamine phosphate] in solvent B [5%
acetonitrile in triethylamine phosphate] at 1.5 ml/min
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Fig. 5 MALDI-TOF mass
spectra of deglycosylated tryptic
glycopeptides derived from
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b glycopeptide α52–63 (endo
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(PNGase F); d glycopeptide
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252 Glycoconj J (2008) 25:245–257PNGase F, showed that fraction 1-1 corresponded to β9–20
(Fig. 5a) and fraction 1-2 to α76–92 (Fig. 5d) [31, 32].
Fraction 2 was resistant to PNGase F, but, digested with
Endo H, it gave rise to a single [M+H]
+ peak at m/z 1561.3,
corresponding to peptide α52–63 with one GlcNAc residue
attached at αAsn52 (Fig. 5b). It should be noted that
PNGase F does not release N-glycans from Asn residues
that occur as N- or C-terminus in a peptide [33]. MALDI-
TOF-MS analysis of fraction 3, digested with PNGase F,
demonstrated the presence of a single [M+H]
+ peak at m/z
2667.2, corresponding to peptide β21–43 (Fig. 5c) [31, 32].
Although the HPLC profile suggests a poor separation
between fractions 2 and 3 (Fig. 4), MALDI-TOF-MS
analysis of these fractions showed pure α52–63 and β21–
43, respectively. Finally, the released 2AB-derivatized N-
glycans of the fractions 1-1, 1-2, 2, and 3 were subjected to
HPLC analysis on TSKgel amide-80 (normal phase) and
Vydac 301 VHP5410 (weak-anion exchange), and the
results are presented in Table 1.
As is evident from Table 1, the N-glycosylation profiles at
αAsn52 and αAsn78 are highly similar with dominating
Man9GlcNAc2 and Man10GlcNAc2 structures. The N-glyco-
sylation profile of βAsn13 presents similar amounts of Man8–
11GlcNAc2, whereas for βAsn30 the Man9GlcNAc2 structure
strongly dominates. Interestingly, compared with the other
glycosylation sites, βAsn30 contains a very low amount of
Man11GlcNAc2. It seems that the N-glycans in the α-subunit
are more processed than those in the β-subunit. Within the β-
subunit the N-glycans at βAsn13 are more processed than
those at βAsn30. It should be noted that the N-glycan at
αAsn52 in urinary hCG, located at the subunit interface [10,
11], is involved in receptor binding and in steroidogenic
activity [34–36]. As phCG/GS115 is biologically active, the
high-mannose-type N-glycans at αAsn52 seem to replace
efficiently the sialylated glycan at αA s n 5 2i nu r i n a r yh C G .
The difference in processing between βAsn13 and
βAsn30 could be explained in terms of space availability.
Crystallographic studies have shown that the N-glycans at
βAsn13 and βAsn30 are located less than 7 Å from each
other on the outward faces of the two adjacent β-strands
[11]. Due to this proximity, it is postulated that there is a
competition between the mannosyltransferase-directed
growing of the more bulky high-mannose-type chains, as
compared with the complex-type structures in urinary hCG,
at both sites, whereby the faster growing bulky glycan at
βAsn13 might prevent any further processing at βAsn30.
Production and characterization of
15N-phCG/GS115
Performing the culturing protocol using
15NH4Cl/glucose-
glycerol-methanol as nitrogen/carbon sources for the
preparation of phCG in P. pastoris strain GS115, it was
possible to isolate from 3 l culture supernatant about 25 mg
of
15N-phCG/GS115.
The purified protein showed two bands on SDS-PAGE
with apparent molecular masses of 25 kDa and 35 kDa,
corresponding to N-glycosylated α-a n dβ-
15N-phCG/
GS115, respectively (Fig. 6, lane 2). Theoretical masses
of α- and β-
15N-phCG/GS115 (15.9 kDa and 21.3 kDa,
respectively) were calculated considering that a Man9
GlcNAc2 high-mannose-type structure was present at each
N-glycosylation site. Apparent molecular masses are larger
than theoretical masses, presumably because of partial
shielding of the protein moiety, hindering the binding of
SDS to the protein. The
15N incorporation in the labeled
phCG/GS115 was estimated by GLC-EI/MS of a trime-
thylsilylated protein hydrolysate. Six amino acids (valine,
leucine, glycine, serine, threonine, and proline) could be
clearly identified in the TIC chromatogram by comparing
Table 1 Glycan chains occurring at the αAsn52, αAsn78, βAsn13, and βAsn30 sites in phCG/GS115. The quantifications are based on peak
areas of the 2AB-labeled N-glycans in the HPLC chromatograms
Ensemble α52–63 α76–92 β9–20 β21–43 Average phCG
Man8GlcNAc2 992 0 3 6 1 9 1 9
Man9GlcNAc2 41 36 28 51 39 38
Man10GlcNAc2 37 30 27 11 26 27
Man11GlcNAc2 13 25 25 2 16 16
14  
67  
30  
20  
43  
94  
12
Fig. 6 12% SDS-PAGE gel of
purified
15N-phCG/GS115
stained with Coomassie Blue.
Lane 1 indicates the protein
molecular markers (phosphory-
lase B, 94 kDa; bovine serum
albumin, 67 kDa; ovalbumin,
43 kDa; carbonic anhydrase,
30 kDa; trypsin inhibitor,
20.1 kDa; α-lactalbumin,
14.4 kDa). Lane 2 shows
15N-
phCG/GS115 (α-, β-subunits)
Glycoconj J (2008) 25:245–257 253their mass spectra (data not shown) with reference data
[37]. Calculation of the ratio of
15N-enriched / non-enriched
fragments using the mass spectra of the mentioned amino
acids demonstrated that phCG/GS115 was
15N-labeled for
about 70%. The non-completed labeling of the hCG is due
to the fact that the preculturing was performed with
14NH4Cl.
As reported previously for glycoprotein hormones [38–
40], characterization of intact hCG is quite difficult by
MALDI-TOF-MS. Very broad peaks are obtained due to
glycan heterogeneity and also here to the
15N-incorporation
of 70%. A typical mass spectrum of
15N-phCG/GS115
contained peaks corresponding to the α- and β-subunits at
15.9 and 21.3 kDa, respectively (Fig. 7). Unfortunately, the
15N-enrichment of phCG/GS115 could not be detected by
this technique.
The secondary structure of
15N-phCG/GS115 was
studied by circular dichroism (CD), and compared with
urinary hCG. Previous studies carried out on urinary hCG
have suggested that covalent binding of carbohydrate
results in an increase of the optical activity at 207 nm
[41]. As is evident from Fig. 8, the CD spectra of both
compounds, recorded under the same conditions, are
superimposable, indicating that the structure of
15N-phCG/
GS115 is similar to that of urinary hCG. It can be inferred
that
15N-phCG/GS115 possesses the proper assembly of
subunits. The high-mannose-type N-glycans of
15N-phCG/
GS115 [5], being partially phosphorylated, seem to have no
influence on the secondary structure of the protein.
The reconstituted glycohormone showed similar biolog-
ical activities as urinary hCG in terms of receptor binding,
cAMP stimulation and steroidogenesis. The overall confor-
mation of
15N-phCG/GS115 was judged by radioimmuno-
assay using polyclonal antiserum against hCG [17]. All the
RIA curves were analyzed using Graphpad prism software
(version 3.03). As shown in Fig. 9a, the RIA displacement
curve obtained with
15N-phCG/GS115 is parallel to that
observed with an authentic urinary hCG preparation,
suggesting that the overall conformation in
15N-hCG/
GS115 is comparable to that of the natural hormone. To
demonstrate that
15N-phCG/GS115 is biologically active,
its ability to bind to the LH receptor and elicit a biological
response was next determined. As shown in Fig. 9b,
15N-
phCG/GS115 was able to inhibit completely the binding of
125I-hCG to the receptor. Furthermore, the biological
activity was demonstrated by incubating the mouse Leydig
cells with equivalent receptor activities of hCG,
15N-phCG/
GS115 and phCG/GS115 for 4 h, and testosterone secreted
into the medium was determined. Typical dose response
curves are shown in Fig. 9c, where
15N-phCG/GS115,
phCG/GS115, and urinary hCG showed almost identical
activities.
15N-phCG/GS115 has therefore full biological
activity as judged by RIA, RRA, and in vitro bioassays.
The
15N-HSQC NMR spectrum of
15N-phCG/GS115
(Fig. 10) presents a broad chemical shift dispersion of
backbone amide protons from 9.7 to 7.2 ppm, being
characteristic of structured proteins.
15N-phCG/GS115
(with 30 Pro residues and 2 N-termini) contains 233 amino
acid residues that could potentially be observed in a
15N-
HSQC spectrum. In fact, approximately 220 cross-peaks are
observed in the spectrum of Fig. 10, which indicates that
the large hCG (molecular mass 37.2 kDa, including the
oligosaccharide chains and the
15N incorporation) is not
aggregating at the NMR conditions, and that it has
relatively uniform hydrodynamic properties. The cross-
peaks in the
15N-HSQC spectrum show a wide distribution
in peak intensity. Although this could be due to sample
heterogeneity of
15N-phCG/GS115 due to different glyco-
sylation patterns, or partially due to anisotropic tumbling, it
appears more likely that this reflects differences in
dynamics. Approximately 40 NH cross-peaks, that are
more intense than most other signals, are all located in a
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Fig. 7 MALDI-TOF mass spectrum of purified
15N-phCG/GS115.
The matrix consisted of 3,5-dimethoxy-4-hydroxycinnaminic acid
(sinapinic acid, 10 mg/ml) dissolved in acetonitrile-0.3% aqueous
trifluoroacetic acid (50:50, v/v). Before analysis, the sample was
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Fig. 8 CD spectra of urinary hCG (thin line) and
15N-phCG/GS115
(thick line), recorded at room temperature. Samples (0.5 mg) were
dissolved in 300 μl 50 mM sodium phosphate buffer, pH 5.6
254 Glycoconj J (2008) 25:245–257narrow region of the spectrum (F2=8.5–7.8 ppm/F1=125–
130 ppm), and thus show limited chemical shift dispersion.
These residues are likely located in an unstructured highly
mobile part of
15N-phCG/GS115.
The crystallographic structure of dimeric hCG [11]
showed a disordered region with no electron density for
the carboxylic terminal extension of β-hCG (βAsp111-
βGln145). An intense cross-peak can be observed at 8.43/
112.5 ppm, the random coil frequencies for Gly, which can
then be assigned to βGly136. Therefore, we ascribe most of
the intense signals to this part of the protein, which then
demonstrates that the disorder in the X-ray structure is due
to high mobility of hCG.
Final remarks
Until now, the production of labeled proteins for NMR
purposes has been carried out mainly in bacterial systems,
such as E. coli. Previously, also α- and β-hCG have been
expressed in these bacteria [42, 43], and 6–10 mg/l of
 
ng hCG /phCG/
15N-phCG 
Radioimmunoassay with B52/12 MAb 
10
-1  10
0 10
1  10
2  0 
8000 
16000 
24000  urinary hCG 
15N-phCG 
phCG 
 
125 I hCG 
 bound (cpm) 
a    Radioreceptor assay
10
-3 10
-1 10
1
0
10000
20000
urinary hCG 
15N-phCG 
ng urinary hCG/ 
15N-phCG
b
 
125 I hCG 
 bound (cpm)
In vitro  Bioassay
10
-1  10
1 10
3 0 
1000 
2000 
3000 
4000  urinary hCG 
phCG 
15N-phCG 
ng urinary hCG/phCG/
15N-phCG
pg testosterone/ ml 
(mean+S.D n=3)  
c
Fig. 9 Characterization of the
hCG activity of purified
15N-phCG/GS115. a Radioim-
munoassay with B52/12 MAb.
b Receptor binding activity of
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radioactivity bound to the
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Glycoconj J (2008) 25:245–257 255unfolded proteins could be produced. Refolding of each
subunit followed by dimer assembly is then necessary to
obtain an hCG heterodimer. However, non-glycosylated
systems are obtained, usually not fully biologically active
[42], which are not useful in case of studying native
glycoproteins. Also eukaryotic systems were investigated
for hCG expression, e.g. insect cells (α-hCG [44], β-hCG
[45], and hCG [46]) as well as Dictyostelium discoideum
(hCG [47]). hCG has also been expressed in Chinese hamster
ovary (CHO) cells, and its glycosylation pattern was
established [48]. This recombinant hCG is used for in vitro
fertilization treatments [49, 50]. CHO cells [51, 52] were also
used to produce uniformly
13C- and
15N-labeled hCG, but
NMR structures have not been solved. P. pastoris was
selected because this yeast can perform post-translational
modifications, is easier to grow than CHO cells, and requires
media of a simpler formulation. The present investigation has
shown that this choice can generate very efficiently
15N-
labeled hCG to be used in NMR studies.
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